Lantern Pharma Inc. 8-K

What Happened Lantern Pharma Inc. filed a Current Report on Form 8-K on June 2, 2026 to disclose that it used a presentation on June 1, 2026 in connection with discussions about the Harmonic™ Phase 2 clinical trial for its product candidate LP-300. The presentation is furnished as Exhibit 99.1 to the 8-K and is incorporated by reference. The disclosure was made under Regulation FD.

Key Details

• Filing date: June 2, 2026; presentation date: June 1, 2026.
• Topic: presentation relating to the Harmonic™ Phase 2 clinical trial for LP-300.
• Exhibit: Presentation provided as Exhibit 99.1 to the Form 8-K.
• The 8-K did not report earnings, executive changes, or other material financial items.

Why It Matters This filing publicly documents information Lantern Pharma shared about the LP-300 Phase 2 program and ensures fair public disclosure under Regulation FD. Investors who follow Lantern’s drug-development progress should review the attached presentation (Exhibit 99.1) for any clinical updates, timelines, or program details that could affect the company’s development outlook.